Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide

Clinical Lymphoma and Myeloma

Volumn 9, Issue 3, 2009, Pages

  Kurtin, Sandra ^a,b   List, Alan ^c,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cytogenetics; Deletion 5q; Immunomodulatory drug; MDS 001; Oral therapy; Transfusion Independence

Indexed keywords

GROWTH FACTOR; HEMOGLOBIN; IRON; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CANCER RISK; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMOGLOBIN BLOOD LEVEL; HEMOSIDEROSIS; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INFECTION; IRON CHELATION; IRRITABLE COLON; LEUKOCYTE COUNT; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMONIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CASE REPORT; CHROMOSOME 5; GENETICS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROGNOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 5; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 69149102966     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.053     Document Type: Article

References (9)

1. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96:3671-4.
2. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemia evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25:3503-10.
3. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120:1037-46.
4. Solé F, Luño E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90:1168-78.
5. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110:4385-95.
6. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456-65.
7. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549-57.
8. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111:86-93.
9. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005; 352:536-8.